Fox Chase Cancer Center
Academic comprehensive cancer center providing clinical care, basic and translational research, and community outreach. Services include specialized oncology clinical programs (radiation, surgical, and medical oncology), precision oncology and risk-assessment programs, early-phase clinical trials, and a broad research portfolio in cancer biology, targeted therapies, and biomarker discovery.
Industries
N/A
Nr. of Employees
small (1-50)
Fox Chase Cancer Center
Fox Chase Cancer Center, Main Campus, 333 Cottman Avenue, Philadelphia, PA 19111-2497
Patents
Rationally-designed anti-mullerian inhibiting substance type II receptor antibodies
US-9611321-B2
View DetailsCompositions and methods for the prevention of cancer in high risk patients
US-8969304-B2
View Details
Rationally-designed anti-mullerian inhibiting substance type II receptor antibodies
US-9611321-B2
View DetailsCompositions and methods for the prevention of cancer in high risk patients
US-8969304-B2
View DetailsServices
Multidisciplinary clinical care in medical, surgical, and radiation oncology across multiple cancer types.
Enrollment and management of clinical trials including early-phase and investigator-initiated studies.
Risk stratification, screening, and navigation services provided in clinical and community/mobile settings for high-risk populations.
Remote video and telephone consultations to connect patients with clinicians.
Multidisciplinary clinical care in medical, surgical, and radiation oncology across multiple cancer types.
Enrollment and management of clinical trials including early-phase and investigator-initiated studies.
Risk stratification, screening, and navigation services provided in clinical and community/mobile settings for high-risk populations.
Remote video and telephone consultations to connect patients with clinicians.
Expertise Areas
- Radiation oncology
- Surgical oncology (thoracic)
- Precision oncology and molecularly targeted therapy
- Early-phase clinical trial management
Key Technologies
- Intensity-modulated radiation therapy (IMRT)
- Hypofractionated radiotherapy
- Stereotactic radiation
- siRNA functional screening
News & Updates
Scientific symposium marking the 50th anniversary of the Philadelphia chromosome discovery, covering discovery history, molecular characterization, and therapeutic impact.
Study identifying calcium-calmodulin as a rapid activator of Aurora-A kinase with implications for drug combinations.
Focused siRNA screen of an EGFR-interacting network identified targets that sensitize cells to EGFR inhibitors and informed combination trials.
Institution designated as a National Cancer Institute Comprehensive Cancer Center (designation noted historically since 1974).
Scientific symposium marking the 50th anniversary of the Philadelphia chromosome discovery, covering discovery history, molecular characterization, and therapeutic impact.
Study identifying calcium-calmodulin as a rapid activator of Aurora-A kinase with implications for drug combinations.
Focused siRNA screen of an EGFR-interacting network identified targets that sensitize cells to EGFR inhibitors and informed combination trials.
Institution designated as a National Cancer Institute Comprehensive Cancer Center (designation noted historically since 1974).